Kyverna Therapeutics (KYTX) closed at $4.88 on November 6, 2026, up 5.9% from the previous close, on volume of 797,409 shares (30-day average 854,730).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Globe Newswire (Thu, 5-Nov 4:02 PM ET)
Globe Newswire (Fri, 23-Oct 10:30 AM ET)
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
PRNewswire (Thu, 22-Oct 2:21 PM ET)
Globe Newswire (Wed, 21-Oct 7:15 AM ET)
Globe Newswire (Wed, 7-Oct 8:00 AM ET)
Kyverna Highlights 49% Median Walk-Time Improvement at One Year in Stiff Person Syndrome Trial
Market Chameleon (Thu, 24-Sep 3:54 AM ET)
Globe Newswire (Thu, 24-Sep 6:00 AM ET)
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 4:05 PM ET)
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Globe Newswire (Tue, 11-Aug 4:02 PM ET)
Market Chameleon (Mon, 22-Jun 5:42 AM ET)
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Kyverna Therapeutics trades on the NASDAQ stock market under the symbol KYTX.
As of November 6, 2026, KYTX stock price climbed to $4.88 with 797,409 million shares trading.
KYTX has a beta of 2.20, meaning it tends to be more sensitive to market movements. KYTX has a correlation of 0.16 to the broad based SPY ETF.
KYTX has a market cap of $301.80 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that KYTX belongs to (by Net Assets): VTI, IWM, VXF, FESM, VTWO.
KYTX has underperformed the market in the last year with a price return of -31.2% while the SPY ETF gained +10.8%. KYTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -37.0% and -9.5%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
KYTX support price is $4.37 and resistance is $4.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYTX shares will trade within this expected range on the day.
